10/2/2013

Takeda Pharmaceuticals and Lundbeck obtained the FDA's approval to market their serotonin reuptake inhibitor Brintellix, or vortioxetine, as a treatment for major depressive disorder. The approval was based on data from six clinical trials.

Related Summaries